Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by canadafanon May 20, 2020 7:53pm
370 Views
Post# 31054016

RE:RE:RBC 2020 Global Healthcare Conference

RE:RE:RBC 2020 Global Healthcare ConferenceI can not stress enough the importance of any investor,past present or future.
Please go & listen to the Oncoytics RBC Global health conference.
The "market" did like it.
Becuase as has been said, clear and laymans terms of what ONCs drug is all about.
He also hints about multiple-pharma finanical interests lately.

They have ample $ well into next year & do not need to draw down from the market.
Do not tak emy word for it, please listen for yourself.
The moderator Douglas Miehm is the anlaysts who has a outperfor/buy rating on ONC and a target price of $6.00 with a further upside of $18, should they meet addtional , not yet announced targets.

My guess, Doug M will be upgrading that price mid-eary June, once the abstracts and any new "deals" get announced.
JUST My OPIONION.... the $6.00 is something we will see next few weeks.

Bullboard Posts